X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs LUPIN LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA LUPIN LTD ABBOTT INDIA/
LUPIN LTD
 
P/E (TTM) x 33.0 16.8 197.0% View Chart
P/BV x 8.2 3.9 211.1% View Chart
Dividend Yield % 0.8 0.8 103.2%  

Financials

 ABBOTT INDIA   LUPIN LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
LUPIN LTD
Mar-16
ABBOTT INDIA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs6,0152,127 282.8%   
Low Rs3,7071,294 286.5%   
Sales per share (Unadj.) Rs1,236.9304.1 406.8%  
Earnings per share (Unadj.) Rs122.250.4 242.4%  
Cash flow per share (Unadj.) Rs129.060.7 212.5%  
Dividends per share (Unadj.) Rs35.007.50 466.7%  
Dividend yield (eoy) %0.70.4 164.2%  
Book value per share (Unadj.) Rs521.2243.8 213.8%  
Shares outstanding (eoy) m21.25450.58 4.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.95.6 69.9%   
Avg P/E ratio x39.833.9 117.2%  
P/CF ratio (eoy) x37.728.2 133.7%  
Price / Book Value ratio x9.37.0 132.9%  
Dividend payout %28.614.9 192.5%   
Avg Mkt Cap Rs m103,296770,740 13.4%   
No. of employees `0003.016.4 18.1%   
Total wages/salary Rs m3,37021,077 16.0%   
Avg. sales/employee Rs Th8,891.88,379.6 106.1%   
Avg. wages/employee Rs Th1,140.01,289.0 88.4%   
Avg. net profit/employee Rs Th878.31,388.7 63.2%   
INCOME DATA
Net Sales Rs m26,284137,016 19.2%  
Other income Rs m5041,877 26.9%   
Total revenues Rs m26,789138,893 19.3%   
Gross profit Rs m3,66537,535 9.8%  
Depreciation Rs m1444,635 3.1%   
Interest Rs m8446 1.8%   
Profit before tax Rs m4,01734,330 11.7%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,42111,536 12.3%   
Profit after tax Rs m2,59622,707 11.4%  
Gross profit margin %13.927.4 50.9%  
Effective tax rate %35.433.6 105.3%   
Net profit margin %9.916.6 59.6%  
BALANCE SHEET DATA
Current assets Rs m14,44697,790 14.8%   
Current liabilities Rs m4,72553,872 8.8%   
Net working cap to sales %37.032.1 115.4%  
Current ratio x3.11.8 168.4%  
Inventory Days Days5185 60.7%  
Debtors Days Days20121 16.1%  
Net fixed assets Rs m1,11386,379 1.3%   
Share capital Rs m213901 23.6%   
"Free" reserves Rs m10,808105,735 10.2%   
Net worth Rs m11,076109,844 10.1%   
Long term debt Rs m053,739 0.0%   
Total assets Rs m16,241224,378 7.2%  
Interest coverage x497.077.9 637.6%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.60.6 265.0%   
Return on assets %16.010.3 155.4%  
Return on equity %23.420.7 113.4%  
Return on capital %36.321.2 171.4%  
Exports to sales %0.649.1 1.3%   
Imports to sales %12.67.4 169.8%   
Exports (fob) Rs m16267,244 0.2%   
Imports (cif) Rs m3,32210,199 32.6%   
Fx inflow Rs m26871,405 0.4%   
Fx outflow Rs m3,92717,807 22.1%   
Net fx Rs m-3,65953,598 -6.8%   
CASH FLOW
From Operations Rs m2,514-3,690 -68.1%  
From Investments Rs m-800-69,434 1.2%  
From Financial Activity Rs m-80358,126 -1.4%  
Net Cashflow Rs m912-14,998 -6.1%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 75.0 0.2 37,500.0%  
Indian inst/Mut Fund % 7.9 11.3 69.9%  
FIIs % 0.1 31.9 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.1 169.3%  
Shareholders   18,270 98,259 18.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 17, 2017 03:37 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - FDC LTD. COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS